DK2970291T3 - Fremgangsmåder og mellemprodukter til fremstilling af et medikament - Google Patents

Fremgangsmåder og mellemprodukter til fremstilling af et medikament Download PDF

Info

Publication number
DK2970291T3
DK2970291T3 DK14708885.0T DK14708885T DK2970291T3 DK 2970291 T3 DK2970291 T3 DK 2970291T3 DK 14708885 T DK14708885 T DK 14708885T DK 2970291 T3 DK2970291 T3 DK 2970291T3
Authority
DK
Denmark
Prior art keywords
medicine
manufacture
processes
intermediate products
products
Prior art date
Application number
DK14708885.0T
Other languages
English (en)
Inventor
Philip Pye
Haim Cyril Ben
Matteo Conza
Ioannis Nicolaos Houpis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK2970291T3 publication Critical patent/DK2970291T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK14708885.0T 2013-03-15 2014-03-11 Fremgangsmåder og mellemprodukter til fremstilling af et medikament DK2970291T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17
PCT/EP2014/054621 WO2014139970A1 (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Publications (1)

Publication Number Publication Date
DK2970291T3 true DK2970291T3 (da) 2022-08-01

Family

ID=51535892

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14708885.0T DK2970291T3 (da) 2013-03-15 2014-03-11 Fremgangsmåder og mellemprodukter til fremstilling af et medikament

Country Status (19)

Country Link
EP (1) EP2970291B1 (da)
JP (1) JP6777398B2 (da)
KR (2) KR102377688B1 (da)
CN (2) CN112608298A (da)
AU (2) AU2014230935A1 (da)
BR (1) BR112015021856A2 (da)
CA (1) CA2901510C (da)
DK (1) DK2970291T3 (da)
EA (1) EA201591685A1 (da)
ES (1) ES2924193T3 (da)
HR (1) HRP20220628T1 (da)
HU (1) HUE058914T2 (da)
LT (1) LT2970291T (da)
MX (2) MX2015012731A (da)
MY (1) MY194905A (da)
PE (1) PE20151652A1 (da)
SG (2) SG11201507595XA (da)
SI (1) SI2970291T1 (da)
WO (1) WO2014139970A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclic amines as inhibitors of PI3K
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
CN105481862B (zh) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
TWI748941B (zh) * 2015-02-27 2021-12-11 美商英塞特公司 Pi3k抑制劑之鹽及製備方法
LV15201B (lv) * 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-(4-苯氧基)苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018145280A1 (zh) * 2017-02-09 2018-08-16 合肥合源药业有限公司 Flt3激酶抑制剂或其盐的晶型及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
WO2019027860A1 (en) 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
BR112021022347A2 (pt) * 2019-05-21 2022-01-04 Janssen Pharmaceutica Nv Processos e intermediários para a preparação de um inibidor de btk
AU2020280904A1 (en) * 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
CN113200987A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼的制备方法
CN115322226B (zh) * 2022-08-17 2023-08-11 厦门大学 一种共价靶向砷抑制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
EP2201840B1 (en) * 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2954900A1 (en) * 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2590982B1 (en) * 2010-07-09 2017-08-23 The Walter and Eliza Hall Institute of Medical Research Protein kinase inhibitors and methods of treatment
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012283775A1 (en) * 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
AU2013299557B2 (en) * 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
AP2015008381A0 (en) * 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
EP2970291A1 (en) 2016-01-20
WO2014139970A1 (en) 2014-09-18
LT2970291T (lt) 2022-06-10
HUE058914T2 (hu) 2022-09-28
EA201591685A1 (ru) 2016-01-29
KR20150132172A (ko) 2015-11-25
HRP20220628T1 (hr) 2022-06-24
SG11201507595XA (en) 2015-10-29
JP2016510779A (ja) 2016-04-11
JP6777398B2 (ja) 2020-10-28
CA2901510C (en) 2022-11-29
EP2970291B1 (en) 2022-05-11
KR20210123429A (ko) 2021-10-13
PE20151652A1 (es) 2015-11-12
MY194905A (en) 2022-12-22
MX2015012731A (es) 2016-02-18
SI2970291T1 (sl) 2022-07-29
MX2020012596A (es) 2021-02-09
AU2014230935A1 (en) 2015-09-03
AU2018204086A1 (en) 2018-06-28
ES2924193T3 (es) 2022-10-05
KR102377688B1 (ko) 2022-03-22
BR112015021856A2 (pt) 2017-07-18
AU2018204086B2 (en) 2020-03-12
SG10201809696UA (en) 2018-11-29
KR102311329B1 (ko) 2021-10-14
CN105026400A (zh) 2015-11-04
CA2901510A1 (en) 2014-09-18
CN112608298A (zh) 2021-04-06

Similar Documents

Publication Publication Date Title
DK2970291T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af et medikament
DK3328880T3 (da) Terapeutiske midler
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3003699T3 (da) Fodtøjsgenstand og fremgangsmåden til dannelse af genstanden
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3016741T3 (da) Fremgangsmåde til fremstilling af zeolitter og zeotyper
MA40229A (fr) Anticorps anti-tau humanisés
DK3690056T3 (da) Fremgangsmåder og produkter til fremstilling og indgivelse af nukleinsyre
DOS2013000297S (es) Brazalete
DK3174635T3 (da) Fremgangsmåde til fremstilling af en katalysator og katalysatorgenstand
DK3017285T3 (da) Fremgangsmåde samt anordning til fremstilling af en tablet
DK3077513T3 (da) Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf
DK2919589T3 (da) Geleret konfekturevare og fremgangsmåde til fremstilling af en sådan konfekturevare
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3019166T3 (da) A Pharmaceutical Combination for the Treatment of Melanoma
DK3126799T3 (da) Visningsindretning
DK3151943T3 (da) Filterpanel og fremgangsmåde til fremstilling heraf
DK3283058T3 (da) Ribociclib-tablet
DK3262012T3 (da) Et fotokatalytisk betonprodukt og en fremgangsmåde til fremstilling af et fotokatalytisk betonprodukt
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf
KR20180084810A (ko) 정제 세트
UA31197S (uk) Таблетка
DK3231788T3 (da) Fremgangsmåde til fremstilling af et muliefunktionelt produkt og indretning til anvendelse af nævnte fremgangsmåde
DK3003089T3 (da) Smykker og fremgangsmåde til fremstilling af sådanne smykker
DK3140050T3 (da) Dosering med visning